The Vexing Voyage of Vasopressin

Bendicksen, Liam; Kesselheim, Aaron S.; Rome, Benjamin N.

doi:10.1016/j.chest.2022.02.048

Cited by 3 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Natural Peptidesmentioning

confidence: 99%

“…Par Pharmaceutical’s synthetic vasopressin, sold under the brand name Vasostrict, received FDA approval in 2014 [ 70 ]. In September 2021, the FDA approved Eagle’s abbreviated new drug application (ANDA) for vasopressin, and another version was launched in February 2022 by American Regent [ 70 ]. It is administered intravenously (IV) and may have adverse effects, including a decrease in cardiac output, bradycardia, tachyarrhythmias, hyponatremia, and ischemia (coronary, mesenteric, skin, digital) [ 68 ].…”

Section: Natural Peptidesmentioning

confidence: 99%

“…Par Pharmaceutical's synthetic vasopressin, sold under the brand name Vasostrict, received FDA approval in 2014 [70]. In September 2021, the FDA approved Eagle's abbreviated new drug application (ANDA) for vasopressin, and another version was launched Vasopressin binds to its receptor through electrostatic interactions, where the positively charged vasopressin interacts with the negatively charged receptor.…”

Section: Vasopressin (Vasostrict)mentioning

confidence: 99%

“…in February 2022 by American Regent[70]. It is administered intravenously (IV) and may have adverse effects, including a decrease in cardiac output, bradycardia, tachyarrhythmias, hyponatremia, and ischemia (coronary, mesenteric, skin, digital) [68].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Al Musaimi

2024

Biomolecules

View full text Add to dashboard Cite

Peptides continue to gain significance in the pharmaceutical arena. Since the unveiling of insulin in 1921, the Food and Drug Administration (FDA) has authorised around 100 peptides for various applications. Peptides, although initially derived from endogenous sources, have evolved beyond their natural origins, exhibiting favourable therapeutic effectiveness. Medicinal chemistry has played a pivotal role in synthesising valuable natural peptide analogues, providing synthetic alternatives with therapeutic potential. Furthermore, key chemical modifications have enhanced the stability of peptides and strengthened their interactions with therapeutic targets. For instance, selective modifications have extended their half-life and lessened the frequency of their administration while maintaining the desired therapeutic action. In this review, I analyse the FDA approval of natural peptides, as well as engineered peptides for diabetes treatment, growth-hormone-releasing hormone (GHRH), cholecystokinin (CCK), adrenocorticotropic hormone (ACTH), and α-melanocyte stimulating hormone (α-MSH) peptide analogues. Attention will be paid to the structure, mode of action, developmental journey, FDA authorisation, and the adverse effects of these peptides.

show abstract

Section: Natural Peptidesmentioning

confidence: 99%

Section: Natural Peptidesmentioning

confidence: 99%

Section: Vasopressin (Vasostrict)mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Al Musaimi

2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Banting & Best were able to isolate insulin from the pancreatic isles of animals and used it for the treatment of type 1 diabetes. 1 Other examples of early peptide therapeutics include, for example, adrenocorticotropic hormone (ACTH) for the ACTH stimulation test, 2 salmon calcitonin for the treatment of Paget's disease and osteoporosis, 3 oxytocin for inducing childbirth, 4 vasopressin for the treatment of vasodilatory shock, 5 and octreotide for the treatment of acromegaly and neuroendocrine tumours. 6 Over time, an increasing number of peptide therapeutics successfully transitioned into the clinic.…”

Section: Introductionmentioning

confidence: 99%

Biocompatible strategies for peptide macrocyclisation

He,

Ghosh,

Nitsche

2024

Chem. Sci.

View full text Add to dashboard Cite

show abstract

β-Adrenoceptor Agonists Attenuate Thrombin-Induced Impairment of Human Lung Endothelial Cell Barrier Function and Protect the Lung Vascular Barrier during Resuscitation from Hemorrhagic Shock

McGee,

Ogunsina,

Boshra

et al. 2024

Biomedicines

View full text Add to dashboard Cite

β-adrenoceptor (β-AR) agonists are known to antagonize thrombin-induced impairment (TII) of bovine and ovine lung endothelial barrier function. The effects of adrenoceptor agonists and other vasoactive agents on human lung microvascular endothelial cell (HULEC-5a) barrier function upon thrombin exposure have not been studied. Furthermore, it is unknown whether the in vitro effects of adrenoceptor agonists translate to lung protective effects in vivo. We observed that epinephrine, norepinephrine, and phenylephrine enhanced normal and prevented TII of HULEC-5a barrier function. Arginine vasopressin and angiotensin II were ineffective. α1B-, α2A/B-, and β1/2-ARs were detectable in HULEC-5a by RT-PCR. Propranolol but not doxazosin blocked the effects of all adrenoceptor agonists. Phenylephrine stimulated β2-AR-mediated Gαs activation with 13-fold lower potency than epinephrine. The EC50 to inhibit TII of HULEC-5a barrier function was 1.8 ± 1.9 nM for epinephrine and >100 nM for phenylephrine. After hemorrhagic shock and fluid resuscitation in rats, Evans blue extravasation into the lung increased threefold (p < 0.01 vs. sham). Single low-dose (1.8 μg/kg) epinephrine administration at the beginning of resuscitation had no effects on blood pressure and reduced Evans blue extravasation by 60% (p < 0.05 vs. vehicle). Our findings confirm the effects of β-adrenoceptor agonists in HULEC-5a and suggest that low-dose β-adrenoceptor agonist treatment protects lung vascular barrier function after traumatic hemorrhagic shock.

show abstract

The Vexing Voyage of Vasopressin

Cited by 3 publications

References 6 publications

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Biocompatible strategies for peptide macrocyclisation

β-Adrenoceptor Agonists Attenuate Thrombin-Induced Impairment of Human Lung Endothelial Cell Barrier Function and Protect the Lung Vascular Barrier during Resuscitation from Hemorrhagic Shock

Contact Info

Product

Resources

About